Literature DB >> 31341717

CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab.

Murtaza Khan1, Douglas E Ney1, Bette K Kleinschmidt-DeMasters1, Lindsay Horton1, Enrique Alvarez1, Amanda L Piquet1.   

Abstract

Entities:  

Year:  2019        PMID： 31341717      PMCID： PMC6615657          DOI： 10.1212/CPJ.0000000000000639

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  6 in total

1.  Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis.

Authors:  Thomas Wehrum; Lena-Alexandra Beume; Oliver Stich; Irina Mader; Mathias Mäurer; Adam Czaplinski; Cornelius Weiller; Sebastian Rauer
Journal:  Neurology       Date:  2018-01-19       Impact factor: 9.910

2.  B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

Authors:  Sara A J Thompson; Joanne L Jones; Amanda L Cox; D Alastair S Compston; Alasdair J Coles
Journal:  J Clin Immunol       Date:  2009-09-10       Impact factor: 8.317

3.  Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Authors:  Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Elizabeth Fisher; Vesna V Brinar; Gavin Giovannoni; Miroslav Stojanovic; Bella I Ertik; Stephen L Lake; David H Margolin; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

4.  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Authors:  Alasdair J Coles; Cary L Twyman; Douglas L Arnold; Jeffrey A Cohen; Christian Confavreux; Edward J Fox; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Howard L Weiner; Tamara Miller; Elizabeth Fisher; Rupert Sandbrink; Stephen L Lake; David H Margolin; Pedro Oyuela; Michael A Panzara; D Alastair S Compston
Journal:  Lancet       Date:  2012-11-01       Impact factor: 79.321

5.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

Review 6.  Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Authors:  Cristina Guarnera; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2017-07-14       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.